2013-03-05 15:07:11 -

SAN FRANCISCO - March 5, 2013 - Merriman Capital, Inc. ("Merriman"), a wholly
owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that
it has been retained as capital markets advisor to Pharmagen, Inc. ("Pharmagen")
(OTC: PHRX). In this capacity, Merriman will advise Pharmagen management on
various strategic initiatives focused on increasing shareholder value. These
initiatives include the effective engagement of a potentially broader
institutional shareholder base, strategies intended to increase trading
liquidity and evaluating various opportunities, including assessments of their
trading patterns and opportunities to pursue other venues, such as NYSE, NASDAQ
and the OTCQX.

Pharmagen produces sterile injectables and has wholesale distribution
capabilities to which allow the Company to quickly supply shortage prone
markets. Pharmagen also develops over-the-counter nutraceutical products, which
are designed to be taken in conjunction with prescription   medications to
alleviate side effects without drug interaction.

"We are very pleased to add Pharmagen to our rapidly expanding universe of
corporate advisory clients," said Douglas Rogers, Managing Director of
Merriman's Capital Markets Advisory Group.  "Supporting our clients with
corporate brokerage and strategic advisory services relating to their capital
structure, market engagement practices and overall public markets strategy
efforts are the central themes of our advisory platform at Merriman.  We look
forward to sponsoring and supporting the Pharmagen management team in our
capacity as their capital markets advisor."

About Merriman Capital, Inc.
Merriman Capital, Inc. is a corporate advisory-focused registered investment
bank that provides equity and options execution services, market making, and
differentiated research for high growth companies. The firm also provides
capital formation, advisory, and M&A services. Merriman Capital, Inc. is a
wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is the
leading investment banking firm for OTCQX companies. For more information,
please go to  www.merrimanco.com/.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial
Industry Regulatory Authority (FINRA)  www.finra.org/ and the Securities
Investor Protection Corporation (SIPC)  www.sipc.org/.

About Pharmagen, Inc.
Pharmagen, Inc ("Pharmagen"), and wholly owned subsidiaries and operating
divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and
Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the
nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen
is meeting the demand of health provider market through dynamic, independent
wholesale, compounding, and innovative IT solutions.  Nationally focused,
Pharmagen is a dynamic distributor of specialty drugs, compounding and admix
pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the
healthcare provider market. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are hard-to-find due to
drug manufacturers' production shortages.

Note to Investors
This press release contains certain forward-looking statements based on our
current expectations, forecasts and assumptions that involve risks and
uncertainties. This release does not constitute an offer to sell or a
solicitation of offers to buy any securities of the Company. Forward-looking
statements in this release are based on information available to us as of the
date hereof. Our actual results may differ materially from those stated or
implied in such forward-looking statements, due to risks and uncertainties
associated with our business, which include the risk factors disclosed in our
Form 10-K/A filed on April 30, 2012 and the Form 10-Q filed on November
14, 2012. Forward-looking statements include statements regarding our
expectations, beliefs, intentions or strategies regarding the future and can be
identified by forward-looking words such as "anticipate," "believe,"
"could,"
"estimate," "expect," "intend," "may,"
"should," and "would" or similar words.
We assume no obligation to update the information included in this press
release, whether as a result of new information, future events or otherwise. The
Form 10-K/A filed on April 30, 2012 and the Form 10-Q filed on November
14, 2012, together with this press release and the financial information
contained herein, are available on our website, www.merrimanco.com. Please click
on "Investor Relations."
# # #

At Merriman:

Douglas Rogers
Managing Director
Merriman Capital, Inc.
(415) 248-5612

Will Febbo
Chief Operating Officer
Merriman Capital, Inc.
(415) 248-5603

Howard Bernstein
Chief Compliance Officer
Merriman Capital, Inc
(415) 262-1377







This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Merriman Holdings Inc. via Thomson Reuters ONE
[HUG#1683109]